Precision and simplicity in every setting: Our IP-10-based ELISA and lateral flow test empower healthcare providers with reliable, efficient, and accessible solutions for Tuberculosis diagnostic.

Tuberculosis remains one of the top 10 causes of death worldwide and a leading cause of death from a single infectious agent.

  • In 2022, 10.6 million people fell ill with Tuberculosis (TB), and 1.6 million lost their lives.
  • Latent TB affects approximately one-quarter of the global population, with individuals at risk of progressing to active TB.
  • Early and accurate detection and treatment of TB is critical to breaking the chain of transmission and eliminating TB globally.

Our Mission: To support healthcare providers with innovative diagnostic tools that address the global TB challenge.

Three tubes two choices: Choose the diagnostic tool that fits your needs.

RIDA®TB Tubes

Only three blood collection tubes per patient for efficient and reliable T-cell stimulation.

  • Only three induction tubes per patient
  • ESAT-6 and CFP-10 as established and specific antigens
  • IP-10 induction in just 16 hours minimizes waiting times.
  • Vacuum blood collection tubes for direct blood collection

Exclusively compatible with RIDASCREEN® TB and RIDA® QUICK TB

RIDASCREEN® TB ELISA

  • Up to 28 determinations per plate for medium- to high-throughput settings.
  • IP-10 induction in just 16 hours minimizes waiting times.
  • Includes all required reagents in one kit for seamless implementation.
  • Compatible with manual and automated workflows to fit your lab’s needs.

RIDA® QUICK TB Lateral Flow Test

  • Designed for decentralized testing in health care centers, field programs, and mobile units.
  • One test cartridge per patient for straightforward handling and reduced errors.
  • Results in just 15 minutes, allowing immediate decision-making.
  • Up to 100 fold induction compared to IFN-y.
  • Robust colloidal gold technology
    • no need for fluorescence
    • less sensitive to light exposure, ensuring reliability in all settings.
  • Readout and result interpretation with RIDA®Q3 lateral flow reader
  • Supports continuous loading — RIDA®Q3 stays unoccupied during incubation, allowing ongoing workflows.

Our solutions empower healthcare providers to tackle TB in all environments:

  • RIDASCREEN® TB ELISA: Laboratory-based testing for medium- to high-throughput requirements.
  • RIDA® QUICK TB Lateral Flow Test: Rapid, reliable testing for small sample volumes, resource-limited settings or mobile care programs.

Performance

Outstanding performance compared to QuantiFERON®-TB Gold Plus (QFT-Plus)

  • Multicentric diagnostic study with 338 patients from 7 study centers in Germany and South Africa

85.2 % sensitivity in active TB patients vs 71.6 % QFT-Plus
Strong agreement between RIDASCREEN® TB and RIDA®QUICK TB

  • Positive percent agreement 92,1 %
  • Negative percent agreement 98,9 %

PPV and NPV with QTF-Plus

  • Positive percent agreement 96.9 %, Negative percent agreement 86,9 % *

*negative percent agreement lower due to higher sensitivity of the RIDASCREEN® TB in clinically confirmed active TB patients

Start typing and press Enter to search